Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 20, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting held on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,314.29 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 318,039,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 5.58% of total voting rights.
- Shares in Issue: 5,702,708,404 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 800,000 shares for Treasury. This action increases the proportion of Treasury shares to 5.58% of total voting rights. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,702,708,404) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (318,039,158) and its impact on voting rights (5.58%).
- Note that this filing is a transaction report and does not contain quarterly or annual financial performance data.